Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–1 of 1 results
Advanced filters: Author: Aashish Dewan Clear advanced filters
  • The PARP inhibitor olaparib is an approved treatment method for women with BRCA1 and BRCA2 mutation associated cancers. Here the authors show that olaparib can contribute to synthetic viability of cells if PARP1 is inhibited before BRCA2 loss.

    • Xia Ding
    • Arnab Ray Chaudhuri
    • Shyam K. Sharan
    ResearchOpen Access
    Nature Communications
    Volume: 7, P: 1-12